Masato Nakamura

Masato Nakamura

Auto-generated profile, based on publicly available information

Masato Nakamura

Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
OIOsamu Iida
Osamu Iida
MNMasato Nakamura
Masato Nakamura
YYYasutaka Yamauchi
Yasutaka Yamauchi
DKDaizo Kawasaki
Daizo Kawasaki
YYYoshiaki Yokoi
Yoshiaki Yokoi
SNShinsuke Nanto
Shinsuke Nanto
Background—: Recent technical advances have made endovascular treatment (EVT) an alternative first-line treatment for critical limb ischemia. Methods and Results—: A prospective multicenter study was conducted to evaluate the clinical outcomes of 314 Japanese critical limb ischemia patients (mean age, 73±10 years) with infrainguinal arterial lesions who underwent EVT. Patients were enrolled from December 2009 to July 2011 and were followed-up for 12 months. The primary end point was amputation-free survival (AFS) at 12 months. Secondary end points were anatomic, clinical, and hemodynamic measures, including 12-month freedom from major adverse limb events. The 12-month AFS rate was 74%, with body mass index <18.5 (hazard ratio [HR], 2.22; P =0.008), heart failure (HR, 1.73; P =0.04), and wound infection (HR, 1.89; P =0.03) associated with a poor prognosis for AFS. The 12-month major adverse limb event-free rate was 88%, with hemodialysis (HR, 1.98; P =0.005), heart failure (HR, 1.69; P =0.02), and Rutherford classification 6 (HR, 2.25; P =0.002) associated with a poor prognosis for major adverse limb events. The median time for wound healing was 97 days, with body mass index <18.5 (HR, 0.54; P =0.03) and wound infection (HR, 0.60; P =0.04) being significant risk factors for unhealed wounds after EVT. At 12 months, 34% had undergone reintervention (bypass surgery, 2.6%; repeat EVT, 31.7%), and 73% were major adverse event–free. Conclusions—: The high reintervention rate notwithstanding, EVT was an effective treatment for Japanese critical limb ischemia patients with infrainguinal disease, with satisfactory AFS and major adverse limb event-free rates. The results of this study will be helpful for the future evaluation of critical limb ischemia therapy. Clinical Trial Registration—: URL: http://www.umin.ac.jp/ctr . Unique identifier: UMIN000002830.

1 September 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
OIOsamu Iida
Osamu Iida
MNMasato Nakamura
Masato Nakamura
YYYasutaka Yamauchi
Yasutaka Yamauchi
MFMasashi Fukunaga
Masashi Fukunaga
YYYoshiaki Yokoi
Yoshiaki Yokoi
SNShinsuke Nanto
Shinsuke Nanto

1 June 2017 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MNMasato Nakamura
Masato Nakamura
RIRaisuke Iijima
Raisuke Iijima
JAJunya Ako
Junya Ako
TSToshiro Shinke
Toshiro Shinke
HOHisayuki Okada
Hisayuki Okada
HUHiroki Uehara
Hiroki Uehara

1 October 2018 in Atherosclerosis
Verified
Journal Article
Open access
MHMariko Harada-Shiba
Mariko Harada-Shiba
JAJunya Ako
Junya Ako
HAHidenori Arai
Hidenori Arai
AHAtsushi Hirayama
Atsushi Hirayama
YMYoshitaka Murakami
Yoshitaka Murakami
MNMasato Nakamura
Masato Nakamura
Prevalence of familial hypercholesterolemia (FH), a common genetic disorder with a high risk for coronary artery disease (CAD), is high among CAD patients; however, data on FH prevalence among acute coronary syndrome (ACS) patients are limited. EXPLORE-J is the largest registry to diagnose FH among Japanese ACS patients using the 2012 Japan Atherosclerosis Society guidelines. This prospective study consecutively recruited patients between April 2015 and August 2016 at 59 sites. Low-density lipoprotein cholesterol (LDL-C) levels, family history of premature CAD, presence of tendon xanthomas, and Achilles tendon radiograms were recorded at baseline. The prevalence rate of FH in patients with ACS was estimated with 95% CI. Of 1944 analyzed patients (mean age, 66.0 years; men, 80.3%), 52 (2.7% [95% CI: 2.0-3.5]) had FH. Thirty-one (1.6%) had LDL-C ≥180 mg/dL and Achilles tendon thickness (ATT) ≥9 mm, 8 (0.4%) had LDL-C ≥180 mg/dL and family history of premature CAD, 10 (0.5%) had ATT ≥9 mm and family history of premature CAD, and 3 (0.2%) met all the criteria. FH patients were younger than those without FH (59.5 [12.5] vs. 66.2 [12.1] years; p < 0.001). More patients with premature ACS (men, <55 years; women, <65 years) than without (4.7% [95% CI: 2.9-7.2] vs. 2.1% [1.4-3.0]) had FH. FH prevalence is at least five-fold higher in ACS patients than in the general population, especially in patients with premature ACS onset and ATT ≥9 mm. FH screening in ACS patients is therefore clinically important and critical.

25 March 2014 in Cardiovascular Intervention and Therapeutics
Verified
Journal Article
Closed access
PDF file
MNMasato Nakamura
Masato Nakamura
MYMasakazu Yamagishi
Masakazu Yamagishi
TUTakafumi Ueno
Takafumi Ueno
KHKazuhiro Hara
Kazuhiro Hara
SISugao Ishiwata
Sugao Ishiwata
TKTakeshi Kimura
Takeshi Kimura

1 March 2015 in International Journal of Cardiology
Verified
Journal Article
Open access
MNMasato Nakamura
Masato Nakamura
TITakaaki Isshiki
Takaaki Isshiki
TKTakeshi Kimura
Takeshi Kimura
HOHisao Ogawa
Hisao Ogawa
HYHiroyoshi Yokoi
Hiroyoshi Yokoi
SSShigeru Saito
Shigeru Saito
Few studies have examined the effects of on-treatment platelet reactivity on the risk of major adverse cardiovascular events (MACE). We aimed to determine the optimal cutoff value of P2Y12 reaction units (PRUs) to prevent MACE occurring within 3days after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). We performed post-hoc analyses of 1363 patients enrolled in PRASFIT-ACS, which compared the effects of a prasugrel regimen adjusted for Japanese patients (loading dose/maintenance dose: 20mg/3.75mg) with those of clopidogrel (300mg/75mg) on MACE and bleeding events for 24-48weeks after PCI in ACS patients. PRU was serially measured using the VerifyNow® P2Y12 assay and we assessed the relationship between PRU and MACE. Receiver operating characteristic curve analysis showed that PRU ≤262 at 5-12h after ADP receptor antagonist loading was the optimal cutoff value for preventing MACE at up to 3days after PCI. The incidences of MACE were 5.2% and 10.8% in patients with PRU ≤262 or >262, respectively (odds ratio 0.50, 95% confidence interval 0.25-0.99, p<0.01). Significantly more prasugrel-treated patients had lower on-treatment platelet reactivity (defined as PRU ≤262) compared with clopidogrel-treated patients (79.9% vs. 30.4%, p<0.0001). Similar differences were observed between the prasugrel and clopidogrel groups for patients with normal or reduced-function CYP2C19 alleles. The optimal PRU cutoff value for preventing MACE was 262 in Japanese ACS patients. Prasugrel rapidly reduced PRU with a large proportion of patients having low on-treatment platelet reactivity.